Journal article icon

Journal article

Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chronic hepatitis C virus

Abstract:

Objectives: Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in ∼95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower cure rates over 8 weeks (<85%); for these patients, 12 weeks of treatment produces cure rates greater than 95%. We evaluated the lifetime cost-effectiveness of testing for NS5A resistance at baseline and optimizing treatm...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More from this funder
Name:
National Institute for Health Research
Grant:
NF-SI-0515-10005
Publisher:
Elsevier
Journal:
Value in Health More from this journal
Volume:
23
Issue:
2
Pages:
180-190
Publication date:
2019-10-24
DOI:
EISSN:
1524-4733
ISSN:
1098-3015
Language:
English
Keywords:
Pubs id:
pubs:1073317
UUID:
uuid:f4c1b65a-aa41-405d-a3ef-b1b192161c5d
Local pid:
pubs:1073317
Source identifiers:
1073317
Deposit date:
2019-11-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP